Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, 2-Arm Parallel-Group, Multicenter Study With a 24-Week Main Treatment Period and an Extension Assessing the Efficacy and Safety of AVE0010 in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Feb 2023
Price :
$35
*
At a glance
- Drugs Lixisenatide (Primary) ; Insulin; Metformin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms GETGOAL-L
- Sponsors Sanofi
- 12 Feb 2023 Results from a pooled analysis of GetGoal-Duo 1, GetGoal-L, and GetGoal-L-C studies for type 2 diabetes in Asian patients were published in the Diabetes Therapy
- 16 Jun 2020 Results of pooled analysis assessing the efficacy of LIXI vs. placebo as add-on treatment to BI plus minus metformin in Asian and Caucasian patients with T2DM presented at the 80th Annual Scientific Sessions of the American Diabetes Association
- 27 Jul 2016 According to a Sanofi media release, lixisenatide (Adlyxin) has been approved by the US FDA for the treatment of adults with typre 2 diabetes based on results from GetGoal clinical program and ELIXA trial.